C. Langford

KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial

T. Graubert, C. Corless, T. George, 2010 .

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

M. Triggiani, J. Panse, H. Kluin-Nelemans, 2022, Blood advances.

Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial

J. Merker, M. Liedtke, P. Westervelt, 2018, Leukemia.

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

S. Verstovsek, T. George, J. Gotlib, 2019, Blood advances.

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group

A. Vannucchi, J. Gotlib, J. Kiladjian, 2023, Leukemia.